Digma Medical
Noninvasive Procedure for Diabetes Treatment
Company Overview
Snapshot
Founded in January 2013 by Irit Yaniv and Ilan Ben-Oren, Digma Medical operates with 11–50 employees. The company has raised $2.36M across 4 funding rounds from 2 investors.
Business overview
Digma Medical is developing a minimally invasive therapy, Endoscopic Glycemic Management (EGM), for type 2 diabetes. This treatment aims to restore the body’s natural ability to control blood glucose levels by targeting the duodenal submucosa, which is central to nutrient sensing and metabolic signaling. The product consists of a console and a single-use catheter compatible with standard gastrointestinal endoscopes, designed for performance in a standard GI endoscopy suite. Digma Medical operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics, serving healthcare providers, hospitals, and doctors.
Log in to access full profile ›Company Intelligence Q&A
- What is Digma Medical's core technology for diabetes treatment?
- Digma Medical is developing Endoscopic Glycemic Management (EGM), a minimally invasive therapy designed to restore the body’s natural ability to control blood glucose levels by targeting the duodenal submucosa.
- When was Digma Medical founded and by whom?
- Digma Medical was founded in January 2013 by Irit Yaniv and Ilan Ben-Oren.
- Which investors have participated in Digma Medical's funding rounds?
- Digma Medical has received funding from investors including Peregrine Ventures and Accelmed.
- What is the primary market Digma Medical serves?
- Digma Medical primarily serves the healthcare market, focusing on healthcare providers, hospitals, and doctors with its medical device solutions for type 2 diabetes.